STAT3 Inhibitor Design via Local Quality and Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that inhibit the STAT3 pathway lack selectivity for STAT3 over STAT1 and have limitations in potency, solubility, and stability, necessitating the development of new molecules with improved properties for treating cancers with hyper-activated STAT3.
Innovation Solution
A novel compound with a specific core structure and substituents is developed, which selectively inhibits STAT3 while maintaining activity against STAT3-mediated diseases, such as Squamous Cell Carcinoma, with enhanced potency, solubility, and stability compared to prior art compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current compounds that inhibit the STAT3 pathway are used, then STAT3 pathway inhibition is achieved, but selectivity for STAT3 over STAT1 is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions on the core molecular structure. The R group at position 6, R1 at position 7, and X at position 3 are carefully selected to create localized chemical features that enhance STAT3 binding affinity while reducing STAT1 interaction, thereby achieving selectivity through localized structural modifications
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent types, positions, and molecular properties to optimize the compound's selectivity profile. By adjusting parameters such as substituent identity (R, R1, X), molecular weight, and structural configuration, the invention achieves compounds with improved STAT3 over STAT1 selectivity
2Reliability
If prior art compounds are used, then STAT3 inhibition is achieved, but potency is limited
Solution Approach 1:
The patent improves potency by changing key molecular parameters including substituent identity, molecular size, and structural configuration. The systematic optimization of R, R1, and X groups enables the development of compounds with enhanced STAT3 inhibition potency compared to prior art compounds
Solution Approach 2:
The patent creates composite molecular structures by combining the core triazolo[3,4-b][1,3,4]thiadiazine scaffold with various substituent groups (R, R1, X). This composite approach allows integration of multiple functional elements that collectively enhance STAT3 binding affinity and inhibition potency
3Reliability
If prior art compounds are used, then STAT3 pathway inhibition is achieved, but solubility is limited
Solution Approach 1:
The patent addresses solubility by changing molecular parameters such as introducing polar substituents, adjusting molecular weight, and modifying structural flexibility. These parameter changes enhance the compound's solubility properties while maintaining STAT3 inhibition activity, facilitating easier formulation and manufacturing
4Reliability
If prior art compounds are used, then STAT3 pathway inhibition is achieved, but stability is limited
Solution Approach 1:
The patent enhances stability by introducing specific substituents at strategic positions on the molecular structure. The R, R1, and X groups are selected to provide localized protection against metabolic degradation, improving compound stability and half-life while maintaining STAT3 inhibition activity
Solution Approach 2:
The patent creates stable composite molecular structures by combining the core scaffold with substituent groups that enhance metabolic stability. This composite design integrates structural elements that resist degradation, resulting in compounds with improved stability and prolonged duration of action
Data Source
AI summary
Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.